Co-Authors
This is a "connection" page, showing publications co-authored by AYSEGUL A SAHIN and GORDON B MILLS.
Connection Strength
1.080
-
High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clin Cancer Res. 2016 Oct 15; 22(20):5068-5078.
Score: 0.144
-
Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83.
Score: 0.126
-
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics. 2011 Jul 08; 8(1):11.
Score: 0.103
-
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009 May 15; 69(10):4116-24.
Score: 0.089
-
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clin Cancer Res. 2021 06 01; 27(11):3243-3252.
Score: 0.051
-
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
Score: 0.045
-
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018.
Score: 0.041
-
Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016 Nov 22; 7(47):76362-76373.
Score: 0.037
-
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
Score: 0.035
-
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851.
Score: 0.034
-
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3).
Score: 0.033
-
Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. Breast Cancer Res Treat. 2014 Sep; 147(2):381-7.
Score: 0.032
-
Definition of PKC-a, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res. 2014 Sep 01; 74(17):4822-35.
Score: 0.032
-
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
Score: 0.031
-
Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther. 2014 May; 13(5):1382-9.
Score: 0.031
-
Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat. 2014 Jan; 143(1):189-201.
Score: 0.030
-
Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One. 2011; 6(8):e23543.
Score: 0.026
-
Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival. Cancer Prev Res (Phila). 2011 Oct; 4(10):1609-16.
Score: 0.026
-
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011 Jun; 10(6):1093-101.
Score: 0.025
-
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009 Jul 07; 16(1):21-32.
Score: 0.022
-
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res. 2009 Jun 01; 15(11):3654-62.
Score: 0.022
-
High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics. 2009 Feb 19; 2:8.
Score: 0.022
-
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008 Aug 01; 68(15):6084-91.
Score: 0.021
-
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008 Feb; 10(2):138-48.
Score: 0.020